X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (8382) 8382
Newsletter (100) 100
Newspaper Article (16) 16
Dissertation (13) 13
Book Chapter (10) 10
Publication (7) 7
Book / eBook (2) 2
Magazine Article (2) 2
Reference (2) 2
Transcript (2) 2
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
paclitaxel (5894) 5894
humans (5608) 5608
female (3476) 3476
oncology (3229) 3229
animals (2740) 2740
cancer (2689) 2689
pharmacology & pharmacy (2624) 2624
chemotherapy (2587) 2587
paclitaxel - administration & dosage (2416) 2416
male (2059) 2059
middle aged (1832) 1832
pharmacokinetics (1789) 1789
paclitaxel - pharmacokinetics (1706) 1706
aged (1678) 1678
mice (1522) 1522
adult (1505) 1505
nanoparticles (1457) 1457
cell line, tumor (1383) 1383
drug delivery systems (1275) 1275
antineoplastic combined chemotherapy protocols - therapeutic use (1191) 1191
paclitaxel - pharmacology (1016) 1016
treatment outcome (1011) 1011
drugs (1004) 1004
tumors (999) 999
taxol (996) 996
docetaxel (985) 985
breast cancer (978) 978
antineoplastic agents, phytogenic - administration & dosage (959) 959
breast neoplasms - drug therapy (916) 916
antineoplastic agents, phytogenic - pharmacokinetics (906) 906
in-vitro (895) 895
paclitaxel - therapeutic use (894) 894
neoplasms - drug therapy (885) 885
research (872) 872
care and treatment (870) 870
doxorubicin (845) 845
cisplatin (825) 825
analysis (805) 805
therapy (787) 787
dose-response relationship, drug (773) 773
antineoplastic agents (755) 755
antineoplastic agents - administration & dosage (752) 752
medicine & public health (750) 750
paclitaxel - adverse effects (733) 733
drug-delivery (732) 732
antimitotic agents (708) 708
drug therapy (689) 689
carboplatin (679) 679
chemistry, multidisciplinary (674) 674
antineoplastic agents - therapeutic use (662) 662
antineoplastic combined chemotherapy protocols - adverse effects (660) 660
paclitaxel - chemistry (658) 658
rats (646) 646
toxicity (639) 639
antineoplastic agents - pharmacokinetics (629) 629
micelles (628) 628
cancer therapies (627) 627
lung neoplasms - drug therapy (624) 624
trial (616) 616
vehicles (616) 616
ovarian cancer (612) 612
antineoplastic agents - pharmacology (610) 610
pharmacology/toxicology (606) 606
ovarian neoplasms - drug therapy (597) 597
nanoparticles - chemistry (595) 595
drug administration schedule (585) 585
combination (577) 577
drug carriers - chemistry (576) 576
delivery (572) 572
metastasis (571) 571
tissue distribution (571) 571
apoptosis (560) 560
nanoscience & nanotechnology (556) 556
health aspects (554) 554
breast-cancer (550) 550
mice, nude (541) 541
cell survival - drug effects (532) 532
antineoplastic agents, phytogenic - therapeutic use (524) 524
cytotoxicity (523) 523
drug delivery (522) 522
p-glycoprotein (518) 518
breast neoplasms - pathology (516) 516
particle size (508) 508
antineoplastic combined chemotherapy protocols - administration & dosage (471) 471
clinical trials (468) 468
carcinoma, non-small-cell lung - drug therapy (460) 460
mice, inbred balb c (456) 456
antineoplastic agents, phytogenic - pharmacology (453) 453
carcinoma (453) 453
paclitaxel - analogs & derivatives (437) 437
xenograft model antitumor assays (433) 433
gemcitabine (430) 430
expression (427) 427
carboplatin - administration & dosage (424) 424
medicine (424) 424
cells (423) 423
liposomes (416) 416
cell lung-cancer (415) 415
pharmacology (415) 415
aged, 80 and over (414) 414
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (8460) 8460
Japanese (59) 59
Chinese (24) 24
French (18) 18
Korean (9) 9
German (6) 6
Portuguese (4) 4
Spanish (4) 4
Polish (3) 3
Czech (2) 2
Hungarian (2) 2
Dutch (1) 1
Italian (1) 1
Russian (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


11/2000, Volume 39, Issue 5, 23
The current practice for the dose calculation of most anticancer agents is based on body surface area in m, although lower interpatient variation in pharmacokinetic parameters has been reported... 
NSC 95580, pharmacokinetics | Teniposide, pharmacokinetics | Topotecan, pharmacokinetics | Iododoxorubicin, pharmacokinetics | Fluorouracil, pharmacokinetics | Cyclophosphamide, pharmacokinetics | Menogaril, pharmacokinetics | Research and development | Paclitaxel, pharmacokinetics | Epirubicin, pharmacokinetics | Etoposide, pharmacokinetics | Antineoplastics, pharmacokinetics | Busulfan, pharmacokinetics | Docetaxel, pharmacokinetics | Idarubicin, pharmacokinetics | Carboplatin, pharmacokinetics | Cisplatin, pharmacokinetics | Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | CELL LUNG-CANCER | COLONY-STIMULATING FACTOR | BONE-MARROW TRANSPLANTATION | HIGH-DOSE CARBOPLATIN | PHASE-I TRIAL | INTERPATIENT PHARMACODYNAMIC VARIABILITY | LIMITED-SAMPLING MODEL | PHARMACOLOGY & PHARMACY | EPITHELIAL OVARIAN-CANCER | HEXAMETHYLENE BISACETAMIDE NSC-95580 | DNA ADDUCT LEVELS | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Busulfan - pharmacokinetics | Cisplatin - pharmacokinetics | Area Under Curve | Humans | Carboplatin - administration & dosage | Etoposide - administration & dosage | Carboplatin - pharmacokinetics | Antineoplastic Agents - administration & dosage | Busulfan - administration & dosage | Cisplatin - administration & dosage | Animals | Fluorouracil - administration & dosage | Topotecan - pharmacokinetics | Topotecan - administration & dosage | Antineoplastic Agents - pharmacokinetics | Fluorouracil - pharmacokinetics | Etoposide - pharmacokinetics
Book Review
Journal Article
Biomaterials, ISSN 0142-9612, 2008, Volume 29, Issue 9, pp. 1233 - 1241
Journal Article
Clinical Pharmacokinetics, ISSN 0312-5963, 2001, Volume 40, Issue 2, pp. 85 - 104
Journal Article
PloS one, ISSN 1932-6203, 2014, Volume 9, Issue 1, p. e82331
Brain cancer is a devastating disease affecting many people worldwide. Effective treatment with chemotherapeutics is limited due to the presence of the... 
MALIGNANT GLIOMA | CELLS | TRANSPORT | MULTIDISCIPLINARY SCIENCES | BARRIER | METASTASES | ADRIAMYCIN | BIODISTRIBUTION | MODEL | CHEMOTHERAPY | PACLITAXEL | Doxorubicin - blood | Glutathione - pharmacokinetics | Doxorubicin - therapeutic use | Capillaries - pathology | Humans | Brain Neoplasms - pathology | Body Weight - drug effects | Polyethylene Glycols - therapeutic use | Drug Delivery Systems | Brain - blood supply | Glutathione - pharmacology | Time Factors | Doxorubicin - analogs & derivatives | Female | Polyethylene Glycols - pharmacology | Glutathione - therapeutic use | Tissue Distribution - drug effects | Glutathione - analogs & derivatives | Endothelial Cells - metabolism | Polyethylene Glycols - pharmacokinetics | Treatment Outcome | Brain Neoplasms - drug therapy | Doxorubicin - pharmacokinetics | Brain - drug effects | Animals | Mice, Nude | Glioblastoma - pathology | Survival Analysis | Brain - pathology | Cell Proliferation - drug effects | Mice | Brain Neoplasms - ultrastructure | Endothelial Cells - pathology | Glioblastoma - drug therapy | Doxorubicin - pharmacology | Glutathione - blood | Drugs | Plasma physics | Drug delivery systems | Anthracyclines | Thiols | Gliomas | Brain tumors | Drug therapy | Cancer | Vehicles | Nuclear medicine | Bioluminescence | Neurosciences | Brain cancer | Glioblastoma | Drug delivery | Metastasis | Cancer therapies | Doxorubicin | Antioxidants | Blood-brain barrier | Inhibition | Xenobiotics | Glutathione | Medical treatment | Pharmacology | Breast cancer | Disease control | Endothelial cells | Studies | Chemotherapy | Brain research | Diffusion barriers | Medical prognosis | Pharmacokinetics | Tumors
Journal Article
Science (American Association for the Advancement of Science), ISSN 1095-9203, 2010, Volume 328, Issue 5981, pp. 1031 - 1035
Poor penetration of anticancer drugs into tumors can be an important factor limiting their effícacy. We studied mouse tumor models to show that a previously... 
Molecules | Intravenous injections | Medical treatment | REPORTS | Antineoplastics | Antibodies | Liposomes | Dosage | Prostate cancer | Tumors | Cancer | NANOPARTICLES | INTEGRINS | MULTIDISCIPLINARY SCIENCES | MOUSE MODEL | IN-VIVO | DOXORUBICIN | PHAGE DISPLAY | VASCULAR-PERMEABILITY FACTOR | CELL | ENDOTHELIAL GROWTH-FACTOR | DELIVERY | Neoplasms - metabolism | Doxorubicin - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Neuropilin-1 - metabolism | Albumin-Bound Paclitaxel | Humans | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Capillary Permeability - drug effects | Antibodies, Monoclonal - therapeutic use | Antineoplastic Agents - therapeutic use | Paclitaxel - pharmacokinetics | Antineoplastic Agents - administration & dosage | Albumins - therapeutic use | Antibodies, Monoclonal, Humanized | Antineoplastic Agents - pharmacokinetics | Paclitaxel - administration & dosage | Doxorubicin - administration & dosage | Oligopeptides - pharmacokinetics | Antibodies, Monoclonal - pharmacokinetics | Albumins - administration & dosage | Neoplasms - blood supply | Oligopeptides - metabolism | Permeability | Paclitaxel - therapeutic use | Doxorubicin - pharmacokinetics | Neoplasms - drug therapy | Xenograft Model Antitumor Assays | Albumins - pharmacokinetics | Animals | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Mice | Oligopeptides - administration & dosage | Oligopeptides - pharmacology | Trastuzumab | Antimitotic agents | Peptides | Research | Antineoplastic agents | Drug therapy | Health aspects | Chemotherapy | Drugs | Nanoparticles | Side effects | Doxorubicin | Constraining
Journal Article